ES2905558T3 - Procedimientos para el tratamiento de las distrofias corneales - Google Patents

Procedimientos para el tratamiento de las distrofias corneales Download PDF

Info

Publication number
ES2905558T3
ES2905558T3 ES16865232T ES16865232T ES2905558T3 ES 2905558 T3 ES2905558 T3 ES 2905558T3 ES 16865232 T ES16865232 T ES 16865232T ES 16865232 T ES16865232 T ES 16865232T ES 2905558 T3 ES2905558 T3 ES 2905558T3
Authority
ES
Spain
Prior art keywords
nucleic acid
mutation
corneal dystrophy
target nucleic
engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16865232T
Other languages
English (en)
Spanish (es)
Inventor
Andrew Nesbit
Gene Lee
Sun-Young Cho
Larry Dedionisio
Tara Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avellino Lab USA Inc
Original Assignee
Avellino Lab USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avellino Lab USA Inc filed Critical Avellino Lab USA Inc
Application granted granted Critical
Publication of ES2905558T3 publication Critical patent/ES2905558T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3695—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3666—Epithelial tissues other than skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • C12N2533/92—Amnion; Decellularised dermis or mucosa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
ES16865232T 2015-11-13 2016-11-14 Procedimientos para el tratamiento de las distrofias corneales Active ES2905558T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562255310P 2015-11-13 2015-11-13
PCT/US2016/061893 WO2017083852A1 (en) 2015-11-13 2016-11-14 Methods for the treatment of corneal dystrophies

Publications (1)

Publication Number Publication Date
ES2905558T3 true ES2905558T3 (es) 2022-04-11

Family

ID=58696178

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16865232T Active ES2905558T3 (es) 2015-11-13 2016-11-14 Procedimientos para el tratamiento de las distrofias corneales

Country Status (7)

Country Link
US (1) US11987809B2 (cg-RX-API-DMAC7.html)
EP (2) EP3374502B1 (cg-RX-API-DMAC7.html)
JP (2) JP6929865B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180120670A (cg-RX-API-DMAC7.html)
CN (1) CN108699542A (cg-RX-API-DMAC7.html)
ES (1) ES2905558T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017083852A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
KR20230155013A (ko) * 2016-08-20 2023-11-09 아벨리노 랩 유에스에이, 인크. 단일 가이드 RNA, CRISPR/Cas9 시스템, 및 이의 사용방법
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
AU2018280116B2 (en) * 2017-06-05 2025-03-27 Research Institute At Nationwide Children's Hospital Enhanced modified viral capsid proteins
JP7161730B2 (ja) * 2017-06-07 2022-10-27 国立大学法人 東京大学 顆粒状角膜変性症に対する遺伝子治療薬
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019060469A2 (en) * 2017-09-19 2019-03-28 Massachusetts Institute Of Technology CAS9 STREPTOCOCCUS CANIS AS A GENOMIC ENGINEERING PLATFORM WITH NEW PAM SPECIFICITY
US11572574B2 (en) 2017-09-28 2023-02-07 Toolgen Incorporated Artificial genome manipulation for gene expression regulation
EP3690047A4 (en) * 2017-09-28 2021-11-03 Toolgen Incorporated ARTIFICIAL GENOME MANIPULATION FOR GENE EXPRESSION REGULATION
EP3724332A1 (en) * 2017-12-14 2020-10-21 CRISPR Therapeutics AG Novel rna-programmable endonuclease systems and their use in genome editing and other applications
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
SG11202010260XA (en) 2018-04-25 2020-11-27 Childrens Medical Center Abcb5 ligands and substrates
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
CN113646434B (zh) * 2018-12-20 2023-05-30 北京大学 使用加标签的向导rna构建体进行高效基因筛选的组合物和方法
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
DE112020001306T5 (de) * 2019-03-19 2022-01-27 Massachusetts Institute Of Technology Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
AU2020248464A1 (en) * 2019-03-28 2021-10-14 Children's Medical Center Corporation Highly functional manufactured ABCB5+ mesenchymal stem cells
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
EP4065702A4 (en) * 2019-11-27 2024-03-20 The General Hospital Corporation SYSTEM AND METHOD FOR ACTIVATING GENE EXPRESSION
RU2730975C1 (ru) * 2020-02-18 2020-08-26 Ирина Викторовна Булыгина Способ лечения эндотелиально-эпителиальной дистрофии роговицы
WO2023004189A1 (en) * 2021-07-23 2023-01-26 Avellino Lab Usa, Inc. Method for detecting alleles associated with keratoconus
CN116286823A (zh) * 2023-04-04 2023-06-23 尧唐(上海)生物科技有限公司 靶向TGFBI基因的sgRNA、载体及其应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
CA2591550C (en) 1996-06-04 2009-04-28 University Of Utah Research Foundation Monitoring hybridization during pcr
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6018713A (en) 1997-04-09 2000-01-25 Coli; Robert D. Integrated system and method for ordering and cumulative results reporting of medical tests
JP3380744B2 (ja) 1998-05-19 2003-02-24 株式会社日立製作所 センサおよびこれを利用した測定装置
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
US6171112B1 (en) 1998-09-18 2001-01-09 Wyngate, Inc. Methods and apparatus for authenticating informed consent
AU4135600A (en) 1999-03-29 2000-10-16 Genset Prostate cancer associated human fibronectin gene and biallelic markers
US6270970B1 (en) 1999-05-14 2001-08-07 Promega Corporation Mixed-bed solid phase and its use in the isolation of nucleic acids
ATE381626T1 (de) 2000-04-13 2008-01-15 Univ Georgetown Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittel
US8438042B2 (en) 2002-04-25 2013-05-07 National Biomedical Research Foundation Instruments and methods for obtaining informed consent to genetic tests
US20030176650A1 (en) 2001-08-09 2003-09-18 Grosse William M. Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
WO2003046526A1 (de) 2001-11-28 2003-06-05 Graffinity Pharmaceuticals Ag Spr-sensorflächenträger
US6943417B2 (en) 2003-05-01 2005-09-13 Clemson University DNA-based memory device and method of reading and writing same
US20050019757A1 (en) 2003-06-12 2005-01-27 Stolarchuk Danylo J. Contaminant detection apparatus
WO2005015198A1 (ja) 2003-08-06 2005-02-17 Nippon Telegraph And Telephone Corporation 多孔質材料を用いた分子の検出方法ならびに該多孔質材料及び該多孔質材料の製造方法
CA2544129A1 (en) 2003-10-22 2005-05-06 The Regents Of The University Of California Methods for preparing and functionalizing nanoparticles
WO2005047534A2 (en) 2003-10-28 2005-05-26 Bayer Healthcare Ag Methods and compositions for the response prediction of malig-nant neoplasia to treatment
EP1541528A1 (en) 2003-12-08 2005-06-15 Institut Jozef Stefan Quasi-one-dimensional polymers based on the metal-chalcogen-halogen system
US20060057604A1 (en) 2004-03-15 2006-03-16 Thinkfar Nanotechnology Corporation Method for electrically detecting oligo-nucleotides with nano-particles
MXPA06013440A (es) 2004-05-19 2007-06-12 Vp Holding Llc Sensor optico con estructura estratificada de plasmon para deteccion mejorada de grupos quimicos por dispersion raman intensificada por superficie.
US7713849B2 (en) 2004-08-20 2010-05-11 Illuminex Corporation Metallic nanowire arrays and methods for making and using same
US7332329B2 (en) 2004-09-24 2008-02-19 Wisconsin Alumni Research Foundation Versatile substrate for SPR detection
WO2006096011A1 (en) 2005-03-08 2006-09-14 Medigenes Co., Ltd. PHARMACEUTICAL COMPOSITION FOR TREATING AVELLINO CORNEA DYSTROPHY COMPRISING AN ANTIBODY AGAINST TGF-β
JP2006250668A (ja) 2005-03-10 2006-09-21 Tatsuro Endo 非標識バイオチップ
EP1715326A1 (en) 2005-04-22 2006-10-25 Universität Heidelberg Sensor chip with connected non-metallic particles comprising a metallic coating
WO2007002567A2 (en) 2005-06-23 2007-01-04 Nanosphere, Inc. Selective isolation and concentration of nucleic acids from complex samples
KR20070076532A (ko) 2006-01-18 2007-07-24 메디제네스(주) 각막이영양증 진단용 ｄｎａ 칩
CN101374850A (zh) 2006-01-18 2009-02-25 株式会社美迪基尼斯 用于角膜营养不良诊断的dna芯片
WO2007109702A2 (en) 2006-03-21 2007-09-27 Washington State University Research Foundation Genetic polymorphisms in the corticotropin-releasing hormone(crh) gene as markers for improving beef marbling score and/or subcutaneous fat depth
EP1932922A1 (de) 2006-12-13 2008-06-18 Desitin Arzneimittel GmbH Schnelltest zum Nachweis von DNA-Sequenzen
EP2115123A4 (en) 2007-01-16 2010-07-07 Applied Biosystems Llc SELECTIVE LYSE OF SPERM CELLS
US7898658B2 (en) 2007-01-23 2011-03-01 The Regents Of The University Of California Platform for chemical and biological sensing by surface-enhanced Raman spectroscopy
KR100891096B1 (ko) 2007-02-13 2009-03-31 삼성전자주식회사 올리고머 프로브 어레이 및 이의 제조 방법
JP5222599B2 (ja) 2007-07-20 2013-06-26 株式会社日立ハイテクノロジーズ 核酸分析デバイス及びそれを用いた核酸分析装置
CN101144812B (zh) 2007-10-17 2012-02-22 中国科学院光电技术研究所 一种局域表面等离子体生化传感器的制作方法
US20120231537A1 (en) 2008-04-30 2012-09-13 Gradalis, Inc. Highly Pure Plasmid DNA Preparations
KR101251538B1 (ko) 2009-04-17 2013-04-08 (주)아벨리노 아벨리노 각막이상증 진단용 프라이머
US8865402B2 (en) 2009-08-26 2014-10-21 Clemson University Research Foundation Nanostructured substrates for surface enhanced raman spectroscopy (SERS) and detection of biological and chemical analytes by electrical double layer (EDL) capacitance
KR101125212B1 (ko) 2010-10-01 2012-03-21 (주)아벨리노 아벨리노 각막이상증 진단용 시스템
KR20130027281A (ko) 2011-09-07 2013-03-15 (주)에스엘에스 원추각막 검사 방법 및 키트
US9895451B2 (en) 2011-12-02 2018-02-20 Yale University Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof
AU2013308770B2 (en) 2012-08-29 2019-01-17 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
PL2771468T3 (pl) 2012-12-12 2015-07-31 Broad Inst Inc Inżynieria systemów, metod i zoptymalizowanych kompozycji kierujących dla manipulacji sekwencjami
EP2921557B1 (en) 2012-12-12 2016-07-13 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
ES2786193T3 (es) 2012-12-12 2020-10-09 Broad Inst Inc Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
KR102385934B1 (ko) * 2013-02-19 2022-04-13 칠드런'즈 메디컬 센터 코포레이션 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포
EP2975117B1 (en) 2013-03-11 2018-01-10 JCR Pharmaceuticals Co., Ltd. Method for producing human corneal epithelium sheet
NZ712727A (en) 2013-03-14 2017-05-26 Caribou Biosciences Inc Compositions and methods of nucleic acid-targeting nucleic acids
CA2910489A1 (en) 2013-05-15 2014-11-20 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
KR20160029112A (ko) 2013-07-09 2016-03-14 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 멀티플렉스 rna-가이드된 게놈 조작
WO2015021426A1 (en) * 2013-08-09 2015-02-12 Sage Labs, Inc. A crispr/cas system-based novel fusion protein and its application in genome editing
EP3872192A1 (en) * 2013-11-15 2021-09-01 Avellino Lab USA, Inc. Methods for multiplex detection of alleles associated with ophthalmic conditions
AU2014361781B2 (en) * 2013-12-12 2021-04-01 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
US20150225801A1 (en) * 2014-02-11 2015-08-13 California Institute Of Technology Recording and mapping lineage information and molecular events in individual cells
SG10201806498RA (en) * 2014-06-27 2018-08-30 Univ California Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
WO2016049024A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
GB2531454A (en) 2016-01-10 2016-04-20 Snipr Technologies Ltd Recombinogenic nucleic acid strands in situ
MX2017016921A (es) * 2015-07-02 2018-04-10 Univ Johns Hopkins Tratamientos basados en crispr / cas9.
WO2017062983A1 (en) 2015-10-09 2017-04-13 The Children's Hospital Of Philadelphia Compositions and methods for treating huntington's disease and related disorders
KR102827276B1 (ko) 2016-08-03 2025-07-01 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
WO2020046861A1 (en) 2018-08-27 2020-03-05 Avellino Lab Usa, Inc. Crispr/cas9 systems, and methods of use thereof
US20210222171A1 (en) 2016-08-20 2021-07-22 Avellino Lab Usa, Inc. Crispr/cas9 systems, and methods of use thereof
WO2019165322A1 (en) 2018-02-22 2019-08-29 Moore Tara Crispr/cas9 systems, and methods of use thereof
KR20230155013A (ko) 2016-08-20 2023-11-09 아벨리노 랩 유에스에이, 인크. 단일 가이드 RNA, CRISPR/Cas9 시스템, 및 이의 사용방법
US20220056440A1 (en) 2016-08-20 2022-02-24 Tara Moore Crispr gene editing for autosomal dominant diseases
CN106282383B (zh) 2016-10-08 2019-05-31 山东省眼科研究所 Krt12基因在检测圆锥角膜中的应用
MX2019006157A (es) 2016-11-28 2019-11-21 Univ Texas Prevención de la distrofia muscular mediante la edición de genes mediada por crispr/cpf1.
WO2018200980A1 (en) 2017-04-28 2018-11-01 Avellino Lab Usa, Inc. Methods for detecting alleles associated with keratoconus
EP3676378A4 (en) 2017-08-31 2021-06-09 The New York Genome Center PROCEDURES AND COMPOSITIONS USING CRIMP-CPF1 AND PAIRED GUIDE-CRISPR-RNA FOR PROGRAMMABLE GENOMIC DELETIONS

Also Published As

Publication number Publication date
WO2017083852A1 (en) 2017-05-18
EP3374502B1 (en) 2021-10-27
US11987809B2 (en) 2024-05-21
EP3374502A4 (en) 2019-07-10
EP3374502A1 (en) 2018-09-19
JP2018534114A (ja) 2018-11-22
WO2017083852A8 (en) 2018-05-31
US20190085288A1 (en) 2019-03-21
CN108699542A (zh) 2018-10-23
JP2021183626A (ja) 2021-12-02
JP7239649B2 (ja) 2023-03-14
EP4036228A1 (en) 2022-08-03
JP6929865B2 (ja) 2021-09-01
KR20180120670A (ko) 2018-11-06

Similar Documents

Publication Publication Date Title
ES2905558T3 (es) Procedimientos para el tratamiento de las distrofias corneales
JP2024041905A (ja) 一本鎖ガイドＲＮＡ、ＣＲＩＳＰＲ／Ｃａｓ９システム、及びそれらの使用方法
Giannelli et al. Cas9/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9. PHP. B-based delivery
Rodrigues et al. Modeling PRPF31 retinitis pigmentosa using retinal pigment epithelium and organoids combined with gene augmentation rescue
CN110248957B (zh) 经人工操纵的sc功能控制系统
AU2020364157A1 (en) Cells with sustained transgene expression
WO2020046861A1 (en) Crispr/cas9 systems, and methods of use thereof
US20210032612A1 (en) CRISPR/Cas9 Systems, and Methods of Use Thereof
US20200149041A1 (en) Gene Therapy Drug for Granular Corneal Degeneration
JP7393770B2 (ja) ゲノム編集による２つの最も高頻度に見られるｕｓｈ２ａ突然変異の修正
Chae et al. Precise Progerin Targeting Using RfxCas13d: A Therapeutic Avenue for Hutchinson–Gilford Progeria Syndrome
WO2022072458A1 (en) Crispr/cas9 targeted excision of the intronic ctg18.1 trinucleotide repeat expansion of tcf4 as a therapy in fuchs' endothelial corneal dystrophy
US20230407279A1 (en) Crispr/cas9 targeted excision of the intronic ctg18.1 trinucleotide repeat expansion of tcf4 as a therapy in fuchs' endothelial corneal dystrophy
WO2021214066A1 (en) Compositions for use in treating autosomal dominant best1-related retinopathies
JP6956995B2 (ja) ゲノム編集方法
Kowalczyk et al. Genetics and Gene Therapy of the TGFBI Corneal Dystrophies
HK1259885A1 (en) Methods for the treatment of corneal dystrophies
Giacalone Treating retinal disease
Pan CRISPR/Cas9 Mediated Engineering of MECP2 in a Human Neuronal Cell Line
Messineo Development of a gene targeting strategy (Recombinase-Mediated CAssette Exchange) to generate cellular models of MYH9-related disease
McLain et al. Amanda M. Kowalczyk, M. Andrew Nesbit
HK40014170B (zh) 经人工操纵的sc功能控制系统